

---

## **Azacytidine Enhances Sensitivity Response to Imatinib in BCR/ABL positive CML Cell Line**

**Hamid Ali Nagi Al-Jamal<sup>1\*</sup>, Wan Rohani Wan Taib<sup>2</sup>, Siti Asmaa Mat Jusoh<sup>3</sup>, Aziee Sudin<sup>3</sup> and Muhammad Farid Johan<sup>3</sup>**

<sup>1</sup>*Diagnostic and Biomedicine, Faculty of Health Sciences, Block Hafsa, Universiti Sultan Zainal Abidin, Gong Badak campus, Kuala Nerus, 21300, Terengganu, Malaysia*

<sup>2</sup>*Institute for Community Health Development, Universiti Sultan Zainal Abidin, Gong Badak campus, Kuala Nerus, 21300, Terengganu, Malaysia*

<sup>3</sup>*Department of Hematology, School of Medical Sciences, Kubang Kerian, 16150, Kelantan, Malaysia*

Azacytidine (5-Aza) is a chemotherapeutic drug that has been known to restore the expression of Tumour suppressor genes by de-methylation and shown clinical efficacy in Myelodysplastic syndrome (MDS) [1-3]. Currently, 5-Aza is being used in UK for the treatment of some adults with MDS, chronic myelocytic leukemia (CML) and acute myelocytic leukemia (AML) [4]. Majority of CML patients treated with imatinib, a BCR/ABL inhibitor would develop resistance under prolonged therapy. Signal transducer and activator of transcription 3 (STAT3) is an oncogenic transcription factor that is constitutively activated in various human cancers including hematological malignancies. Activation of STAT3 represents an important mechanism of imatinib resistant [5]. Methylation of *SHP-1* is involved in the constitutive activation of STAT3 [6], and a low level of *SHP-1* is not sufficient to inhibit activated STAT3 [7]. Epigenetic silencing of *SHP-1* also plays a role in the development of resistance to imatinib in BCR/ABL positive CML cells [8].

Here we evaluated the expression of *SHP-1* gene and its methylation status with sensitivity response of resistant CML cell lines to imatinib before and after treatment with 5-Aza. For this purpose, BCR/ABL positive CML cell lines, K562 and K562-R, an imatinib resistant cell lines were treated with 5-Aza. Cytotoxicity of imatinib and apoptosis were determined by MTS and Annexin-V, respectively. Gene expression analysis was detected by real time-PCR, STATs activity using Western blot and methylation status of *SHP-1* gene by pyrosequencing analysis. There was a significant hypomethylation of *SHP-1* gene in K562-R+5-Aza cells compared to other cells ( $p=0.003$ ), Table 1.

Table 1: Pyrosequencing analysis results showing a significant hypomethylation (p=0,003) in 6 CpG islands of SHP-1 gene in K562-R+5-Aza cells compared to other cells.

Sample ID	CpG-11	CpG-10	CpG-9	CpG-8	CpG-7	CpG-6	Min	Max
K562	23.2	62.8	76.5	64.1	47.9	52.9	23.2	76.5
K562-R	37.6	45.2	82.6	64.9	62.3	50.5	37.6	82.6
K562-R+5-Aza	5.0	3.4	3.2	5.2	5.4	0.0	0.0	5.4
Low Meth Control	6.8	6.9	2.7	10.5	8.3	5.9	2.7	10.5
High Meth Control	93.7	94.0	92.5	74.5	83.3	93.8	74.5	94.0

Gene expression analysis indicates a significant re-expression of *SHP-1* gene (p=0.001) after treatment of K562-R cells with 5-Aza (K562-R+5-Aza cells), Fig 1. Interestingly, the re-expression of *SHP-1* in K562-R+5-Aza cell lines, was associated with STAT3 inactivation and higher sensitivity to imatinib. In conclusion, 5-Aza could enhance efficacy of imatinib on BCR/ABL CML cells through re-expression of *SHP-1* gene and inhibition of STAT3 signaling that could be a new target in cancers treatment.




Fig. 1: Box plot depicts the results of real time-PCR, it shows a significant re-expression of *SHP-1* gene (p=0.001) in K562-R+5-Aza cells compared to other cells.

**Keywords:** 5-Aza, Resistance, *SHP-1*, STAT3

\* **Correspondence:** aljamalhamid@unisza.edu.my

## Acknowledgements

This study was funded by Fundamental Research Grant Scheme (FRGS) 203/PPSP/6171164 from Ministry of Higher Education, Malaysia.

## References:

1. Kiziltepe, T., et al., *5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells*. *Mol Cancer Ther*, 2007. **6**: p. 1718-1727.
2. Stresemann, C., et al., *Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine*. *International journal of cancer Journal international du cancer*, 2008. **123**: p. 8-13.
3. Khan, H., et al., *Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes*. *Seminars in hematology*, 2013. **50**: p. 16-37.
4. Lund, K., et al., *DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML*. *Genome biology*, 2014. **15**: p. 406.
5. Bewry, N.N., et al., *Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance*. *Mol Cancer Ther*, 2008. **7**: p. 3169-3175.
6. Chim, C. S., et al., *SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway*. *Blood*, 2004. **103**: p. 4630-4635.
7. Han, Y., et al., *Restoration of shp1 expression by 5-AZA-2'-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma*. *Leukemia*, 2006. **20**: p. 1602-1609.
8. Esposito, N., et al., *SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia*. *Blood*, 2011. **118**: p. 3634-3644.